RIPK2 dictates insulin responses to tyrosine kinase inhibitors in obese mice
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
ABSTRACTTyrosine kinase inhibitors (TKIs) used in cancer are also being investigated in diabetes. TKIs can improve blood glucose control in diabetic cancer patients, but the specific kinases that alter blood glucose or insulin are not clear. We sought to define the role of Receptor Interacting Serine/Threonine Kinase 2 (RIPK2) in mouse models of insulin resistance. We tested the TKI gefitinib, which inhibits RIPK2 activity, in WT,Nod1-/-, Nod2-/-andRipk2-/-mice fed an obesogenic high fat diet. Gefitinib lowered blood glucose during a glucose tolerance test (GTT) in a NOD-RIPK2-independent manner in all obese mice. However, gefitinib lowered glucose-stimulated insulin secretion only in obeseRipk2-/-mice. Gefitinib had no effect on insulin secretion in obese WT,Nodi-/-, orNod2-/-mice. Hence, genetic deletion ofRipk2promoted the insulin sensitizing potential of gefitinib, since this TKI lowered both blood glucose and insulin only inRipk2-/-mice. Gefitinib did not alter the inflammatory profile of pancreas, adipose, liver or muscle tissues in obeseRipk2-/-mice compared to obese WT mice. We also tested imatinib, a TKI which does not inhibit RIPK2 activity, in obese WT mice. Imatinib lowered blood glucose during a GTT, consistent with TKIs lowering blood glucose independently of RIPK2. However, imatinib increased glucose-stimulated insulin secretion during the glucose challenge. These data show that multiple TKIs lower blood glucose, where actions of TKIs on RIPK2 dictate divergent insulin responses, independent of tissue inflammation. Our data shows that RIPK2 limits the insulin sensitizing effect of gefitinib, whereas imatinib increased insulin secretion.
